AcuraStem Gets $3.7 Million Grant to Treat ALS
June 20, 2018 - als
AcuraStem Inc., a biotech association formed in Monrovia, has perceived a $3.7 million fast-track extend to rise a diagnosis for Lou Gehrig’s disease.
The pointing medicine startup announced Jun 18 that it had perceived a investigate extend from a National Institute of Neurological Disorders and Stroke.
The extend will support a growth of a novel tiny proton compound, famous as AS2015, to provide patients with a genetic form of amyotrophic parallel sclerosis (ALS), or Lou Gehrig’s disease, in further to frontotemporal dementia.
AcuraStem, founded in 2016, was co-founded by Dr. Justin Ichida, partner highbrow of branch dungeon and regenerative medicine during a Keck School of Medicine of USC, where he oversees a investigate lab in his name.
Its pointing platform, iNeuroRx, employs a patient’s branch cells in and with modernized appurtenance training to learn drugs for neurodegenerative diseases.
AcuraStem was comparison as a finalist this month in a 2018 Start-Up Stadium for intensity biotech partners and investors during a BIO International Convention in Boston.
Health business contributor Dana Bartholomew can be reached during firstname.lastname@example.org. Follow him on Twitter @_DanaBart.